Skip to main content
Clinical Trials/NCT02532348
NCT02532348CompletedNot Applicable

Platelets Study: Influence of the Antiretroviral Treatment on the Platelet Physiology During HIV Infection

Centre Hospitalier Universitaire de Saint Etienne1 site in 1 country133 target enrollmentStarted: August 2011Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
133
Locations
1
Primary Endpoint
Plasmatic level of sCD40L

Study Overview

Brief Summary

HIV infection is associated with an immune activation and an inflammatory response - despite an active antiretroviral therapy - which may lead notably but not exclusively to cardiovascular diseases. It has been shown that the use of Protease Inhibitors (PI) instead of Non Nucleosidic Inhibitors (NNRTI) may increase the risk of myocardial infarction. Platelets may play a role in the occurrence of the inflammatory state: they contain big amounts of chemokines, growth factors, and adhesion proteins. Today, the contribution of platelets to the inflammatory state associated with HIV infection has been little studied. Thus, it has been shown that platelets in HIV patients are able to release interleukin (IL)-18. The group has shown with others that the platelet function could be altered during HIV infection. Inversely, it doesn't know how antiretroviral therapy interacts with platelets.

The aim of the study is to evaluate, according to the antiretroviral therapy, the impact on the platelets activation markers.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Unchanged antiretroviral therapy for at least one year
  • Plasmatic viral load < 40 copies/ml.
  • signature of informed consent

Exclusion Criteria

  • Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HVC) coinfection

Outcomes

Primary Outcomes

Plasmatic level of sCD40L

Time Frame: day 1

Comparison of plasmatic level of soluble Cluster Differentiation (sCD40L) between 2 groups : HIV patients treated by antiretroviral therapy and HIV patients untreated. sCD40L is measured by enzyme linked immunosorbent assay (ELISA) in ng/ml.

Secondary Outcomes

  • sCD40L level(day 1)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials